​

Maravai LifeSciences (MRVI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRVI Stock Forecast

Maravai LifeSciences (MRVI) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $4.50, with a high of $4.50 and a low of $4.50. This represents a 36.78% increase from the last price of $3.29.

$3 $4 $5 $6 $7 $8 $9 $10 High: $4.5 Avg: $4.5 Low: $4.5 Last Closed Price: $3.29

MRVI Stock Rating

Maravai LifeSciences stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (50.00%), 6 Hold (42.86%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 6 7 Strong Sell Sell Hold Buy Strong Buy

MRVI Price Target Upside V Benchmarks

TypeNameUpside
StockMaravai LifeSciences36.78%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$4.50$4.75
Last Closing Price$3.29$3.29$3.29
Upside/Downside-36.78%44.38%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-56--11
Feb, 26-56--11
Jan, 26-56--11
Dec, 25-56--11
Nov, 25-56--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 15, 2025Brandon CouillardWells Fargo$4.50$3.6124.65%36.78%
Mar 21, 2025Stifel Nicolaus$5.00$2.27120.26%51.98%
May 09, 2024Catherine SchulteRobert W. Baird$10.00$8.8712.74%203.95%
Dec 14, 2022Deutsche Bank$25.00$15.0366.33%659.88%
Dec 07, 2022RBC Capital$22.00$12.5076.00%568.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 15, 2025Wells FargoOverweightOverweighthold
May 13, 2025Craig-HallumBuyBuyhold
Dec 19, 2024GuggenheimNeutralinitialise
Oct 08, 2024UBSUnderperformUnderperformhold
Aug 27, 2024Wells FargoOverweightinitialise
Aug 13, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Aug 08, 2024UBSNeutralNeutralhold
Jun 03, 2024JefferiesBuyBuyhold
May 29, 2024RBC CapitalOutperformOutperformhold
Feb 23, 2024William BlairOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.59$1.67$-0.90$-1.05$-0.24---
Avg Forecast$1.52$1.79-$-0.08$-0.07$-0.02$0.01$-0.03
High Forecast$1.57$1.97-$-0.07$0.01$-0.01$0.01$-0.02
Low Forecast$1.47$1.59-$-0.10$-0.16$-0.02$0.01$-0.03
Surprise %4.61%-6.70%-1212.50%242.86%---

Revenue Forecast

$0 $190M $380M $570M $760M $950M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$799.24M$883.00M$288.94M$259.19M$49.87M---
Avg Forecast$779.14M$883.43M$279.27M$260.15M$265.12M$294.94M$342.21M$359.90M
High Forecast$798.64M$949.75M$281.86M$260.50M$280.96M$296.49M$342.21M$390.57M
Low Forecast$762.46M$805.34M$274.21M$259.90M$233.46M$293.39M$342.21M$316.39M
Surprise %2.58%-0.05%3.46%-0.37%-81.19%---

Net Income Forecast

$-150M $-60M $30M $120M $210M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$182.04M$220.21M$-119.03M$-144.85M$-130.77M---
Avg Forecast$134.92M$209.76M$-119.03M$-11.08M$-9.49M$-2.05M$976.11K$-3.30M
High Forecast$161.90M$251.71M$-95.22M$-8.86M$1.73M$-1.52M$1.11M$-2.78M
Low Forecast$107.94M$167.81M$-142.83M$-13.30M$-20.70M$-2.58M$842.24K$-3.66M
Surprise %34.92%4.98%-1207.27%1278.24%---

MRVI Forecast FAQ

Is Maravai LifeSciences stock a buy?

Maravai LifeSciences stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 6 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Maravai LifeSciences is a favorable investment for most analysts.

What is Maravai LifeSciences's price target?

Maravai LifeSciences's price target, set by 14 Wall Street analysts, averages $4.5 over the next 12 months. The price target range spans from $4.5 at the low end to $4.5 at the high end, suggesting a potential 36.78% change from the previous closing price of $3.29.

How does Maravai LifeSciences stock forecast compare to its benchmarks?

Maravai LifeSciences's stock forecast shows a 36.78% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Maravai LifeSciences over the past three months?

  • March 2026: 0% Strong Buy, 45.45% Buy, 54.55% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 45.45% Buy, 54.55% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 45.45% Buy, 54.55% Hold, 0% Sell, 0% Strong Sell.

What is Maravai LifeSciences’s EPS forecast?

Maravai LifeSciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.02, marking a -91.67% decrease from the reported $-0.24 in 2025. Estimates for the following years are $0.01 in 2027, and $-0.03 in 2028.

What is Maravai LifeSciences’s revenue forecast?

Maravai LifeSciences's average annual revenue forecast for its fiscal year ending in December 2026 is $294.94M, reflecting a 491.47% increase from the reported $49.87M in 2025. The forecast for 2027 is $342.21M, and $359.9M for 2028.

What is Maravai LifeSciences’s net income forecast?

Maravai LifeSciences's net income forecast for the fiscal year ending in December 2026 stands at $-2.052M, representing a -98.43% decrease from the reported $-131M in 2025. Projections indicate $976.11K in 2027, and $-3.298M in 2028.